Brokerage firm Emkay Global has maintained a 'Buy' rating on Metropolis Healthcare with a target price of Rs 675. This outlook follows the company’s recent Q1 FY27 results, where it reported a 17% rise in revenue. The brokerage anticipates continued growth driven by rising testing volumes and improved profit margins, though competition remains a key factor for investors to track.
Emkay Global Financial Services has reaffirmed its positive outlook on Metropolis Healthcare, maintaining a 'Buy' rating with a target price of Rs 675 per share. This update follows the company's recent performance for the first quarter of the 2027 fiscal year, which showcased steady growth in both revenue and profit.
In the April-June 2026 quarter, Metropolis Healthcare reported revenue of Rs 450 crore, marking a 17% increase compared to the same period last year. The company's profit after tax rose by 26% to Rs 56.9 crore. A significant highlight for investors was the improvement in operational efficiency, with the profit margin expanding by 210 basis points to reach 25.2%.
Strategic Focus on Growth
The company is currently focused on a volume-led growth strategy. Management has guided for annual revenue growth of 14% to 15% through the 2027 fiscal year. A central part of this strategy involves prioritizing the 'TruHealth' segment and specialty testing, which are expected to drive long-term value. Metropolis has also been investing heavily in its digital platforms. Data suggests these channels are attracting a more valuable customer base compared to traditional, offline-only methods, helping the company improve its customer acquisition and retention.
Risks and Market Context
While the brokerage remains optimistic, the Indian diagnostics sector is marked by high competitive intensity. Both large chains and smaller, localized labs are competing aggressively for market share. For investors, it is important to monitor how the company manages this competition. Additionally, the business faces potential risks from regulatory changes, such as price caps on medical tests, which could limit revenue.
Operational success is another factor. The company frequently engages in small, regional acquisitions to expand its network. The challenge lies in integrating these new centers effectively without increasing costs or affecting service quality. Furthermore, volatility in input costs, including logistics and material expenses, remains a factor that can put pressure on profit margins if not managed efficiently.
As of August 27, 2026, the stock closed at Rs 574.85 on the National Stock Exchange (NSE). With the brokerage setting a target of Rs 675, the focus for shareholders will now shift to whether the company can sustain its volume growth and maintain high operational efficiency in the upcoming quarters.